Relationship between bone resorption, oxidative stress and inflammation in severe COPD exacerbation.

[1]  S. Muro,et al.  Impact of COPD Exacerbations on Osteoporosis Assessed by Chest CT Scan , 2012, COPD.

[2]  M. Decramer,et al.  COPD, bone metabolism, and osteoporosis. , 2011, Chest.

[3]  W. MacNee,et al.  New paradigms in the pathogenesis of chronic obstructive pulmonary disease I. , 2009, Proceedings of the American Thoracic Society.

[4]  A. Falus,et al.  Gene expression profiling of experimental asthma reveals a possible role of paraoxonase-1 in the disease. , 2009, International immunology.

[5]  D. Shale,et al.  Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease , 2009, Chronic respiratory disease.

[6]  Thierry Troosters,et al.  COPD as a Lung Disease with Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early Intervention , 2008, COPD.

[7]  E. Wouters,et al.  Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. , 2007, Respiratory medicine.

[8]  A. Agustí.  Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). , 2007, Proceedings of the American Thoracic Society.

[9]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[10]  Bartolome Celli,et al.  Profiling serum biomarkers in patients with COPD: associations with clinical parameters , 2007, Thorax.

[11]  S. Bojesen,et al.  C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[12]  N. Anthonisen,et al.  C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease , 2006, Thorax.

[13]  S. Muro,et al.  Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. , 2005, American journal of respiratory and critical care medicine.

[14]  O. Erel,et al.  A new automated colorimetric method for measuring total oxidant status. , 2005, Clinical biochemistry.

[15]  J. Friedland,et al.  Matrix metalloproteinases in destructive pulmonary pathology , 2005, Thorax.

[16]  E. Pehlivan,et al.  Factors affecting survival of hospitalised patients with COPD , 2005, European Respiratory Journal.

[17]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[18]  E. Wouters,et al.  Body composition and mortality in chronic obstructive pulmonary disease. , 2005, The American journal of clinical nutrition.

[19]  A. Ionescu,et al.  Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[20]  J. Delaissé,et al.  A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. , 2004, Bone.

[21]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[22]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[23]  E. Piitulainen,et al.  Circulating monocytes from healthy individuals and COPD patients , 2003, Respiratory research.

[24]  X. Busquets,et al.  Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[25]  E. Wouters,et al.  Chronic obstructive pulmonary disease • 5: Systemic effects of COPD , 2002, Thorax.

[26]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[27]  D. Biskobing.  COPD and osteoporosis. , 2002, Chest.

[28]  P. Barnes,et al.  New drugs for asthma, allergy and COPD , 2001 .

[29]  J. Foidart,et al.  Matrix metalloproteinases and TIMP‐1 production by peripheral blood granulocytes from COPD patients and asthmatics , 2001, Allergy.

[30]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[31]  H. Saito,et al.  The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor- α System in Patients with Chronic Obstructive Pulmonary Disease , 2000 .

[32]  P. Delmas,et al.  Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  R. Eastell,et al.  Bone Metabolism and Osteoporosis , 1998 .

[34]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[35]  W. MacNee,et al.  Systemic oxidative stress in asthma, COPD, and smokers. , 1996, American journal of respiratory and critical care medicine.

[36]  C. Christiansen,et al.  Immunoassay for quantifying type I collagen degradation products in urine evaluated. , 1994, Clinical chemistry.

[37]  R. Stockley,et al.  NEUTROPHILS FROM SUBJECTS WITH CHRONIC OBSTRUCTIVE LUNG DISEASE SHOW ENHANCED CHEMOTAXIS AND EXTRACELLULAR PROTEOLYSIS , 1987, The Lancet.

[38]  B. Greene,et al.  12 MONTH FOLLOW-UP OF MEBENDAZOLE THERAPY FOR ONCHOCERCIASIS , 1981, The Lancet.

[39]  A. Stefanović,et al.  Paraoxonase-1 (PON1) activity, but not PON1Q192R phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population , 2006, Clinical chemistry and laboratory medicine.

[40]  M. Recep,et al.  Serum Malonyldialdehyde and Paraoxonase Levels in Chronic Obstructive Pulmonary Disease , 2005 .

[41]  W. MacNee,et al.  Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. , 2005, Proceedings of the American Thoracic Society.

[42]  A. Agustí.  Systemic effects of chronic obstructive pulmonary disease. , 2001, Novartis Foundation symposium.

[43]  E. Wouters,et al.  Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[44]  R. Burgeson.  New collagens, new concepts. , 1988, Annual review of cell biology.